Investigation of the pharmacogenetic influence on the course of treatment of depressive patients using different sequencing and array methods

Investigation of the pharmacogenetic influence on the course of treatment of depressive patients using different sequencing and array methods - PharmgenTRD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036105

Enrollment

200

Registered

2025-02-21

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32

Interventions

Group 1: Patients suffering from depression (F32.2. and F33.2.) who are treated as inpatients in the Department of Psychiatry, Psychosomatics and Psychotherapy at Frankfurt University Hospital. Upon i

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: F32.2., F33.2, age>18 years, ability to consent to a written declaration of consent

Exclusion criteria

Exclusion criteria: Exclusion diagnoses: F60.x, F61.x, F2x.x, F31.x; F43.1

Design outcomes

Primary

Measure	Time frame
All cause discontinuation of the antidepressant	—

Secondary

Measure	Time frame
- Reason for discontinuation of the antidepressant - Number of clinical events (TDM, switch, augmentation, combination, escalating procedures ECT, (es)ketamine, rTMS) - Long-read sequencing detection of genotype compared to commercial test - Intestinal microbiological composition and metabolomics, determined by bacterial DNA (and potentially RNA) and liquid chromatography with mass spectrometry coupling (LC-MS), both obtained from stool material. Comparison of non-normal versus normal metabolizers, comparison of non-responders versus responders, comparison of actionable genotype versus non-actionable genotype for the antidepressant used. - Before-after knowledge test of physicians to validate the training material on pharmacogenetics	—

Measure

Time frame

- Reason for discontinuation of the antidepressant - Number of clinical events (TDM, switch, augmentation, combination, escalating procedures ECT, (es)ketamine, rTMS) - Long-read sequencing detection of genotype compared to commercial test - Intestinal microbiological composition and metabolomics, determined by bacterial DNA (and potentially RNA) and liquid chromatography with mass spectrometry coupling (LC-MS), both obtained from stool material. Comparison of non-normal versus normal metabolizers, comparison of non-responders versus responders, comparison of actionable genotype versus non-actionable genotype for the antidepressant used. - Before-after knowledge test of physicians to validate the training material on pharmacogenetics

—

Countries

Germany

Contacts

Public ContactAndreas Reif

Universitätsklinikum Frankfurt

Andreas.Reif@unimedizin-ffm.de069-6301-5222

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026